Immatics Achieves Clinical Proof-Of-Concept For TCER Pipeline: IMA402 (PRAME) 30% cORR, IMA401 (MAGEA4/8) Up To 29% cORR; Initiates Phase 1b And Plans Combo In sqNSCLC

ARYA Sciences Acquisition Corp. -14.24% Pre

ARYA Sciences Acquisition Corp.

IMTX

10.18

10.30

-14.24%

+1.18% Pre
Immatics Achieves Clinical Proof-Of-Concept For TCER Pipeline: IMA402 (PRAME) 30% cORR, IMA401 (MAGEA4/8) Up To 29% cORR; Initiates Phase 1b And Plans Combo In sqNSCLC
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via